Want to see PL:CLN full AI Analyst Report?

Celon Pharma SA (CLN) Price & Analysis

1 Followers

CLN Stock Chart & Stats

zł20.95

Market closed

zł20.95

Day’s Range― - ―

52-Week Rangezł18.50 - zł24.75

Previous CloseN/A

VolumeN/A

Average Volume (3M)15.54K

Market Cap

zł1.07B

Enterprise Valuezł1.15B

Total Cash (Recent Filing)zł9.09M

Total Debt (Recent Filing)zł53.68M

Price to Earnings (P/E)9.7

Beta0.51

Next Earnings

Sep 16, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.43%

Share Statistics

EPS (TTM)2.05

Shares Outstanding53,911,500

10 Day Avg. Volume8,893

30 Day Avg. Volume15,545

Financial Highlights & Ratios

PEG Ratio-0.11

Price to Book (P/B)3.02

Price to Sales (P/S)5.22

P/FCF Ratio-35.85

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.55

Revenue Forecast (FY)zł275.94M

Bulls Say, Bears Say

Bulls Say

Strong Gross Profit MarginA strong gross profit margin indicates effective cost management and pricing power, which can support long-term profitability as the company scales.

Low LeverageLow leverage provides financial flexibility and reduces risk, allowing the company to invest in growth opportunities without significant debt burden.

Revenue Growth PotentialHigh revenue growth potential indicates strong demand for products and successful market penetration, supporting long-term business expansion.

Bears Say

Negative Revenue GrowthNegative revenue growth suggests challenges in maintaining sales momentum, which can hinder long-term business sustainability and market competitiveness.

Profitability ChallengesOngoing profitability challenges indicate operational inefficiencies and may limit the company's ability to reinvest in growth and innovation.

Cash Flow Management IssuesPoor cash flow management can strain financial resources, limiting the company's ability to fund operations and strategic initiatives over the long term.

Celon Pharma SA News

Celon Pharma SA (8RP) Q4 Earnings Cheat Sheet

Celon Pharma SA (8RP) is scheduled to report 4th quarter earnings on 03/29/2023. Regarding Q4 estimates, Wall Street...

3y ago

CLN FAQ

What was Celon Pharma SA’s price range in the past 12 months?

Celon Pharma SA lowest stock price was zł18.50 and its highest was zł24.75 in the past 12 months.

What is Celon Pharma SA’s market cap?

Celon Pharma SA’s market cap is zł1.07B.

When is Celon Pharma SA’s upcoming earnings report date?

Celon Pharma SA’s upcoming earnings report date is Sep 16, 2026 which is in 72 days.

How were Celon Pharma SA’s earnings last quarter?

Currently, no data Available

Is Celon Pharma SA overvalued?

According to Wall Street analysts Celon Pharma SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Celon Pharma SA pay dividends?

Celon Pharma SA pays a Annually dividend of zł0.298 which represents an annual dividend yield of 0.43%. See more information on Celon Pharma SA dividends here

What is Celon Pharma SA’s EPS estimate?

Celon Pharma SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Celon Pharma SA have?

Celon Pharma SA has 53,911,500 shares outstanding.

What happened to Celon Pharma SA’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Celon Pharma SA?

Currently, no hedge funds are holding shares in PL:CLN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Celon Pharma SA

Celon Pharma S.A. operates as a fully-integrated pharmaceutical firm, undertaking the investigation, development, production, and distribution of diverse medicinal formulations. Its business model is structured around two principal areas: generic drug offerings and innovative therapeutic solutions. The company's product line addresses a range of health challenges, including oncological conditions, neurological disorders, diabetes, and other metabolic complaints. Established in 2002, this enterprise is situated in Lomianki, Poland, and functions as a subsidiary of Glatton Sp. z o.o.